Patient Perspectives on Switching from Infliximab to Infliximab-dyyb in Patients with Rheumatologic Diseases in the United States.

Jason ChauThomas DelateTaylor OtaBharati Bhardwaja

Published in: ACR open rheumatology (2019)

Overall, patients reported satisfaction with switching from infliximab to infliximab-dyyb, but concerns regarding safety and efficacy were expressed. Patient involvement in the switching decision-making process may allay concerns and enhance biosimilar uptake.

Keyphrases

ulcerative colitis
decision making
case report
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
patient reported outcomes
patient reported